Tranquis Therapeutics Announces Initiation of Phase 1 Study of TQS-168

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Tranquis Therapeutics, a clinical stage private immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases today announced the initiation of dosing in a Phase 1 clinical study of TQS-168 in healthy volunteers. "This is an important milestone for Tranquis...

Click to view original post